Treatment of human immunodeficiency virus (HIV)-associated nephropathy

Paul L. Kimmel, Juan P. Bosch, Joseph A. Vassalotti

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Patients with human immunodeficiency virus (HIV) nephropathy (HIVN) face improved outlooks both before and after starting renal replacement therapy for end-stage renal disease, compared with the situation a little over a decade and a half before, when the disease was first recognized. Therapy with cyclosporin, glucocorticoids, and angiotensin-converting enzyme inhibitors provides the prospect of longer courses of renal insufficiency for patients with HIVN, and perhaps the hope of blunting progression of the disease when patients are treated early. Trials of patients with biopsy-proven HIVN are important to evaluate further the role of such newer therapies. HIV-infected patients with end-stage renal disease have been treated with hemodialysis, peritoneal dialysis, and renal transplantation. The course of therapy for dialysis patients may be improving, but ultimately depends on the stage of the viral illness. The disparities in the demographic composition of the patient populations probably underlies findings reported from different centers. Transplantation is currently a low-priority treatment option for HIV-infected patients with ESRD, but several studies provide fascinating insights into vital-host interactions.

Original languageEnglish
Pages (from-to)446-458
Number of pages13
JournalSeminars in Nephrology
Issue number4
StatePublished - 1998
Externally publishedYes


Dive into the research topics of 'Treatment of human immunodeficiency virus (HIV)-associated nephropathy'. Together they form a unique fingerprint.

Cite this